PURPOSE: Graft-versus-host disease (GVHD) is major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). Atorvastatin is a potent immunomodulatory agent that holds promise as a novel and safe agent for acute GVHD prophylaxis. PATIENTS AND METHODS: We conducted a phase II trial to evaluate the safety and efficacy of atorvastatin administration for GVHD prophylaxis in both adult donors and recipients of matched sibling allogeneic HCT. Atorvastatin (40 mg per day orally) was administered to sibling donors, starting 14 to 28 days before the anticipated first day of stem-cell collection. In HCT recipients (n = 30), GVHD prophylaxis consisted of tacrolimus, short-course methotrexate, and atorvastatin (40 mg per day orally). RESULTS: Atorvastatin administration in healthy donors and recipients was not associated with any grade 3 to 4 adverse events. Cumulative incidence rates of grade 2 to 4 acute GVHD at days +100 and +180 were 3.3% (95% CI, 0.2% to 14.8%) and 11.1% (95% CI, 2.7% to 26.4%), respectively. One-year cumulative incidence of chronic GVHD was 52.3% (95% CI, 27.6% to 72.1%). Viral and fungal infections were infrequent. One-year cumulative incidences of nonrelapse mortality and relapse were 9.8% (95% CI, 1.4% to 28%) and 25.4% (95% CI, 10.9% to 42.9%), respectively. One-year overall survival and progression-free survival were 74% (95% CI, 58% to 96%) and 65% (95% CI, 48% to 87%), respectively. Compared with baseline, atorvastatin administration in sibling donors was associated with a trend toward increased mean plasma interleukin-10 concentrations (5.6 v 7.1 pg/mL; P = .06). CONCLUSION: A novel two-pronged strategy of atorvastatin administration in both donors and recipients of matched sibling allogeneic HCT seems to be a feasible, safe, and potentially effective strategy to prevent acute GVHD.
PURPOSE:Graft-versus-host disease (GVHD) is major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). Atorvastatin is a potent immunomodulatory agent that holds promise as a novel and safe agent for acute GVHD prophylaxis. PATIENTS AND METHODS: We conducted a phase II trial to evaluate the safety and efficacy of atorvastatin administration for GVHD prophylaxis in both adult donors and recipients of matched sibling allogeneic HCT. Atorvastatin (40 mg per day orally) was administered to sibling donors, starting 14 to 28 days before the anticipated first day of stem-cell collection. In HCT recipients (n = 30), GVHD prophylaxis consisted of tacrolimus, short-course methotrexate, and atorvastatin (40 mg per day orally). RESULTS:Atorvastatin administration in healthy donors and recipients was not associated with any grade 3 to 4 adverse events. Cumulative incidence rates of grade 2 to 4 acute GVHD at days +100 and +180 were 3.3% (95% CI, 0.2% to 14.8%) and 11.1% (95% CI, 2.7% to 26.4%), respectively. One-year cumulative incidence of chronic GVHD was 52.3% (95% CI, 27.6% to 72.1%). Viral and fungal infections were infrequent. One-year cumulative incidences of nonrelapse mortality and relapse were 9.8% (95% CI, 1.4% to 28%) and 25.4% (95% CI, 10.9% to 42.9%), respectively. One-year overall survival and progression-free survival were 74% (95% CI, 58% to 96%) and 65% (95% CI, 48% to 87%), respectively. Compared with baseline, atorvastatin administration in sibling donors was associated with a trend toward increased mean plasma interleukin-10 concentrations (5.6 v 7.1 pg/mL; P = .06). CONCLUSION: A novel two-pronged strategy of atorvastatin administration in both donors and recipients of matched sibling allogeneic HCT seems to be a feasible, safe, and potentially effective strategy to prevent acute GVHD.
Authors: A Bacigalupo; T Lamparelli; P Bruzzi; S Guidi; P E Alessandrino; P di Bartolomeo; R Oneto; B Bruno; M Barbanti; N Sacchi; M T Van Lint; A Bosi Journal: Blood Date: 2001-11-15 Impact factor: 22.113
Authors: Joseph Pidala; Jongphil Kim; Heather Jim; Mohamed A Kharfan-Dabaja; Taiga Nishihori; Hugo F Fernandez; Marcie Tomblyn; Lia Perez; Janelle Perkins; Mian Xu; William E Janssen; Anandaraman Veerapathran; Brian C Betts; Frederick L Locke; Ernesto Ayala; Teresa Field; Leonel Ochoa; Melissa Alsina; Claudio Anasetti Journal: Haematologica Date: 2012-06-11 Impact factor: 9.941
Authors: Sawsan Youssef; Olaf Stüve; Juan C Patarroyo; Pedro J Ruiz; Jennifer L Radosevich; Eun Mi Hur; Manuel Bravo; Dennis J Mitchell; Raymond A Sobel; Lawrence Steinman; Scott S Zamvil Journal: Nature Date: 2002-11-07 Impact factor: 49.962
Authors: Ming-Tseh Lin; Barry Storer; Paul J Martin; Li-Hui Tseng; Ted Gooley; Pei-Jer Chen; John A Hansen Journal: N Engl J Med Date: 2003-12-04 Impact factor: 91.245
Authors: Matthias Edinger; Petra Hoffmann; Joerg Ermann; Kathryn Drago; C Garrison Fathman; Samuel Strober; Robert S Negrin Journal: Nat Med Date: 2003-08-17 Impact factor: 53.440
Authors: E Holler; M G Roncarolo; R Hintermeier-Knabe; G Eissner; B Ertl; U Schulz; H Knabe; H J Kolb; R Andreesen; W Wilmanns Journal: Bone Marrow Transplant Date: 2000-02 Impact factor: 5.483
Authors: M K Levings; R Sangregorio; F Galbiati; S Squadrone; R de Waal Malefyt; M G Roncarolo Journal: J Immunol Date: 2001-05-01 Impact factor: 5.422
Authors: Sherif S Farag; Mohammad Abu Zaid; Jennifer E Schwartz; Teresa C Thakrar; Ann J Blakley; Rafat Abonour; Michael J Robertson; Hal E Broxmeyer; Shuhong Zhang Journal: N Engl J Med Date: 2021-01-07 Impact factor: 91.245
Authors: Bernard Lawrence Marini; Sung Won Choi; Craig Alan Byersdorfer; Simon Cronin; David G Frame Journal: Biol Blood Marrow Transplant Date: 2014-11-20 Impact factor: 5.742
Authors: S Seo; M Boeckh; B E Storer; M M Schubert; M Rotta; B M Sandmaier; M Mielcarek Journal: Bone Marrow Transplant Date: 2015-01-19 Impact factor: 5.483